 |
Venofer® (iron sucrose injection, USP) is a first-line IV iron choice for patients with iron deficiency anemia undergoing chronic hemodialysis and receiving supplemental erythropoietin therapy. Only Venofer® supports treatment safety and simplicity with all of these features:
- Over 50 years of worldwide clinical experience
- Dextran and preservative free
- Available in convenient single-dose vials
- Nondialyzable
|
|
|
|
- No test dose required
- Administration by slow IV push undiluted over
5 minutes (20 mg/min) or by infusion diluted in normal saline over at
least 15 minutes |
|
|
|
- Safety and efficacy confirmed in US clinical trials in iron-deficient patients tolerant and intolerant to other IV irons, on long-term hemodialysis, receiving supplemental erythropoietin therapy
|
IMPORTANT SAFETY INFORMATION
Venofer® (iron sucrose injection, USP) is contraindicated in patients with evidence of iron overload, in patients with known hypersensitivity to Venofer® or any of its inactive components, and in patients with anemia not caused by iron deficiency. Hypersensitivity reactions have been reported with injectable iron products. Hypotension has been reported frequently in patients receiving intravenous iron. Hypotension following administration of Venofer® may be related to rate of administration and total dose delivered. In multidose efficacy studies (N=231), the most frequent adverse events, whether or not related to Venofer® administration, were hypotension, cramps/leg cramps, nausea, headache, vomiting, and diarrhea. In postmarketing safety studies (N=1051), the most frequent adverse events reported (>1%) were congestive heart failure, sepsis, and taste perversion.
Please see Full Prescribing Information.
Venofer is manufactured under license from Vifor (International) Inc.
To learn more about Venofer®, click on a link in the column on the left side of this page.
|
